Riskpilot← Back to searchSign inGet full accessSkulle Implants Oy
OYActiveY-tunnus 2416737-4Lemminkäisenkatu 60Technical testing and analysis · NACE 7120Est. 201110 employeeswww.skulleimplants.com
Revenue 2024
EUR 2M
-98% vs 2023
EBITDA margin
16.6%
+230% vs 2023
Equity ratio
-48.2%
Financial strength
Net profit 2024
EUR 0
+100% vs 2023
| Revenue | EUR 2M | -98% |
| EBITDA | EUR 336K | +230% |
| Net profit | EUR 0 | +100% |
| Total assets | EUR 2,6M | -99% |
| Equity | EUR -1,2M | +0% |
| Employees | 10 | — |
Legal name
Skulle Implants Oy
Y-tunnus number
2416737-4
Legal form
Osakeyhtiö
NACE code
7120 · Technical testing and analysis
Founded
30. kesäkuuta 2011
Share capital
EUR 2 882
Employees
10 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on lääketieteellisten laitteiden tutkimus, tuotekehitys, valmistus ja myynti. Yhtiö voi toimintaansa varten omistaa ja hallita arvopapereita ja kiinteistöjä ja käydä niillä kauppaa.
Address
Lemminkäisenkatu 60
Email
juliusz.rakowski@skulleimplants.com
Website
www.skulleimplants.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 866 | 941 | 830 | 127 663 | 2 026 |
| Staff expenses | −370 | −725 | −797 | −562 | −571 |
| EBITDA | −239 | −990 | −846 | −257 | 336 |
| Depreciation & amort. | −211 | −225 | −265 | −257 | −234 |
| EBIT | −450 | −1 215 | −1 110 | −514 | 102 |
| Net financials | −212 | −142 | −72 | −82 | −102 |
| Profit before tax | −662 | −1 357 | −1 183 | −596 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −662 | −1 357 | −1 183 | −596 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 192 | 2 989 | 2 754 | 265 980 | 2 587 |
| Equity | 91 | 531 | 149 | −1 248 | −1 248 |
| Long-term debt | 1 496 | 800 | 739 | 198 955 | 2 952 |
| Short-term debt | 1 604 | 1 658 | 1 867 | 191 812 | 883 |
| Total debt | 3 100 | 2 458 | 2 605 | 390 767 | 3 835 |
EBITDA margin
16.6%
This company
15.8%
Market median
+5% vs market
20202024
Equity ratio
-48.2%
This company
38.2%
Market median
-226% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.78×
This company
1.12×
Market median
-30% vs market
20202024
Debt / equity
3.07×
This company
0.62×
Market median
-395% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JH Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (4) | ||
TP Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
MS | Audit | 2015 – 2022 |
MH Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
KJ | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2026 | |
| Board of Directors | 2026 | |
| Chairperson | 2026 | |
| Former (9) | ||
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2026 – 2026 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Chairperson | 2022 – 2022 | |
| Board of Directors | 2022 – 2026 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2018 – 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 56% | 56% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oy Skulle Group Corporation
Skulle Implants Oy Board members of Skulle Implants Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tommi Petteri Brunila | Chief Executive Officer | 0 companies |
| Matti Samuli Rantanen | Audit | 0 companies |
| Juliusz Henrik Tadeusz Rakowski | Chief Executive Officer | 0 companies |
| Maija Helena Junkola-Lehtonen | Chief Executive Officer | 0 companies |
| Kalle Juhani Laaksonen | Audit | 0 companies |
| Johan Paul Löfgren | Board of Directors | 0 companies |
| Olli Pekka Karhi | Board of Directors | 0 companies |
| Hanna-Marika Nikkilä | Board of Directors | 0 companies |
| Pekka Kalevi Vallittu | Board of Directors | 0 companies |
| Heikki Juhani Salmela | Board of Directors | 0 companies |
| Jukka Petri Olavi Toivanen | Board of Directors | 0 companies |
| Pasi Kalevi Räty | Chairperson | 0 companies |
| Lauri Tapio Sippola | Board of Directors | 0 companies |
| Sirpa Tuulikki Jalkanen | Board of Directors | 0 companies |
| Juha Olavi Reima | Chairperson | 0 companies |
| Roni Juha Kaunismaa | Board of Directors | 0 companies |
| Sakari Kalervo Kotka | Board of Directors | 0 companies |
| Juha-Pekka Nuutinen | Board of Directors | 0 companies |